Literature DB >> 3417793

Scopolamine reduces frontal cortex perfusion.

W G Honer1, I Prohovnik, G Smith, L R Lucas.   

Abstract

While the cognitive deficits of Alzheimer's disease are considered related to a cholinergic deficit, no attempt has yet been made to test the hypothesis that the characteristic regional cerebral blood flow (rCBF) pattern of Alzheimer's disease may also relate to such a deficit. We therefore measured rCBF using the [133Xe] inhalation technique in 15 young normal subjects before and after induction of reversible cholinergic blockade with scopolamine at doses of 6.1 and 7.3 micrograms/kg i.v. Significant cognitive impairment was observed at both doses, while rCBF changes occurred only at the higher dose. Global CBF was significantly reduced 25 min after scopolamine. The pattern of regional change in CBF was not similar to Alzheimer's disease. Rather than a focal parietotemporal deficit as seen in Alzheimer's disease, we observed a predominantly frontal reduction in flow of about 20%. These results suggest that the frontal but not the parietotemporal deficits seen in several dementing conditions may be related to cholinergic dysfunction.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3417793     DOI: 10.1038/jcbfm.1988.110

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  17 in total

Review 1.  Cholinergic modulation of cognition: insights from human pharmacological functional neuroimaging.

Authors:  Paul Bentley; Jon Driver; Raymond J Dolan
Journal:  Prog Neurobiol       Date:  2011-06-17       Impact factor: 11.685

2.  Role of central angiotensin receptors in scopolamine-induced impairment in memory, cerebral blood flow, and cholinergic function.

Authors:  Santoshkumar Tota; Kashif Hanif; Pradeep Kumar Kamat; Abul Kalam Najmi; Chandishwar Nath
Journal:  Psychopharmacology (Berl)       Date:  2012-02-24       Impact factor: 4.530

3.  Effect of tropatepine, an anticholinergic drug, on regional cerebral blood flow in patients with Parkinson's disease.

Authors:  P Celsis; J L Montastruc; O Rascol; J M Senard; J P Marc-Vergnes; A Rascol
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-07       Impact factor: 10.154

4.  The metabolic brain pattern of young subjects given scopolamine.

Authors:  R M Cohen; M Gross; W E Semple; T E Nordahl; T Sunderland
Journal:  Exp Brain Res       Date:  1994       Impact factor: 1.972

Review 5.  Delirium.

Authors:  D Taylor; S Lewis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-07       Impact factor: 10.154

Review 6.  Cerebrovascular reactivity to carbon dioxide in Alzheimer's disease.

Authors:  Lidia Glodzik; Catherine Randall; Henry Rusinek; Mony J de Leon
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

7.  Differential cholinergic regulation in Alzheimer's patients compared to controls following chronic blockade with scopolamine: a SPECT study.

Authors:  T Sunderland; G Esposito; S E Molchan; R Coppola; D W Jones; J Gorey; J T Little; M Bahro; D R Weinberger
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

8.  Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects.

Authors:  S L Dewey; G S Smith; J Logan; J D Brodie; P Simkowitz; R R MacGregor; J S Fowler; N D Volkow; A P Wolf
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

9.  Potential of pretreatment neural activity in the visual cortex during emotional processing to predict treatment response to scopolamine in major depressive disorder.

Authors:  Maura L Furey; Wayne C Drevets; Elana M Hoffman; Erica Frankel; Andrew M Speer; Carlos A Zarate
Journal:  JAMA Psychiatry       Date:  2013-03       Impact factor: 21.596

10.  The effect of the muscarinic antagonist scopolamine on regional cerebral blood flow during the performance of a memory task.

Authors:  P M Grasby; C D Frith; E Paulesu; K J Friston; R S Frackowiak; R J Dolan
Journal:  Exp Brain Res       Date:  1995       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.